Lifitegrast in Dry Eye Disease: A Paradigm Shift in Targeted Ocular Anti-Inflammatory Therapy

Abstract

Dry Eye Disease (DED) is a multifactorial ocular surface disorder characterized by tear film instability, inflammation, and visual discomfort, significantly impairing quality of life. Lifitegrast, a novel LFA-1 antagonist, represents a targeted therapeutic innovation by directly disrupting T-cell-mediated inflammation via inhibition of the LFA-1/ICAM-1 interaction. This mechanism leads to rapid symptom relief, improved tear film stability, and reduced ocular surface damage. Lifitegrast’s pharmacological profile includes excellent ocular tissue penetration, minimal systemic absorption, and a favorable safety margin. Clinical trials and real-world data confirm its efficacy, especially in moderate to severe DED, refractory cases, Meibomian Gland Dysfunction (MGD), and post-refractive surgery dryness. Compared to cyclosporine, Lifitegrast offers earlier symptom resolution, better tolerability, and patient adherence. While cost and limited long-term data pose challenges, its potential for integration into combination therapies and precision medicine frameworks offers promising future directions. Overall, Lifitegrast exemplifies a paradigm shift in DED management, aligning with the need for personalized, fast-acting, and safe ocular anti-inflammatory treatments.